CA2359360C - In vitro screening method for identifying selective binding partners for 5-ht5-receptors - Google Patents
In vitro screening method for identifying selective binding partners for 5-ht5-receptors Download PDFInfo
- Publication number
- CA2359360C CA2359360C CA2359360A CA2359360A CA2359360C CA 2359360 C CA2359360 C CA 2359360C CA 2359360 A CA2359360 A CA 2359360A CA 2359360 A CA2359360 A CA 2359360A CA 2359360 C CA2359360 C CA 2359360C
- Authority
- CA
- Canada
- Prior art keywords
- binding
- receptors
- receptor
- binding partners
- affinity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000027455 binding Effects 0.000 title claims abstract description 192
- 108010006590 serotonin 5 receptor Proteins 0.000 title claims abstract description 76
- 238000000034 method Methods 0.000 title claims abstract description 44
- 238000012216 screening Methods 0.000 title claims abstract description 21
- 238000000338 in vitro Methods 0.000 title claims description 9
- 238000011282 treatment Methods 0.000 claims abstract description 30
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 53
- 210000004027 cell Anatomy 0.000 claims description 40
- 230000008569 process Effects 0.000 claims description 27
- 101710138068 5-hydroxytryptamine receptor 1D Proteins 0.000 claims description 7
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 7
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 210000003292 kidney cell Anatomy 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 abstract description 23
- 208000019695 Migraine disease Diseases 0.000 abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 40
- 108020003175 receptors Proteins 0.000 description 28
- 102000005962 receptors Human genes 0.000 description 27
- WKZLNEWVIAGNAW-UHFFFAOYSA-N 5-Carboxyamidotryptamine Chemical compound C1=C(C(N)=O)C=C2C(CCN)=CNC2=C1 WKZLNEWVIAGNAW-UHFFFAOYSA-N 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 18
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 16
- 235000001465 calcium Nutrition 0.000 description 16
- 229910052791 calcium Inorganic materials 0.000 description 16
- 239000011575 calcium Substances 0.000 description 16
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 15
- 239000000556 agonist Substances 0.000 description 15
- 230000003834 intracellular effect Effects 0.000 description 15
- 239000000872 buffer Substances 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 230000006870 function Effects 0.000 description 12
- 230000008859 change Effects 0.000 description 11
- 230000000638 stimulation Effects 0.000 description 11
- 230000001270 agonistic effect Effects 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 108091006027 G proteins Proteins 0.000 description 7
- 102000030782 GTP binding Human genes 0.000 description 7
- 108091000058 GTP-Binding Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 210000001130 astrocyte Anatomy 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 description 6
- 102000014384 Type C Phospholipases Human genes 0.000 description 6
- 108010079194 Type C Phospholipases Proteins 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000011835 investigation Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- -1 5-HT5 Proteins 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 5
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- RLJFTICUTYVZDG-UHFFFAOYSA-N Methiothepine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2CC1N1CCN(C)CC1 RLJFTICUTYVZDG-UHFFFAOYSA-N 0.000 description 5
- 230000003491 cAMP production Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 229960003708 sumatriptan Drugs 0.000 description 5
- 102000035038 5-HT1 receptors Human genes 0.000 description 4
- 108091005478 5-HT1 receptors Proteins 0.000 description 4
- 101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 description 4
- 102100027493 5-hydroxytryptamine receptor 1D Human genes 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 101100321769 Takifugu rubripes htr1d gene Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000006957 competitive inhibition Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960000367 inositol Drugs 0.000 description 4
- 230000007257 malfunction Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 239000002287 radioligand Substances 0.000 description 4
- 238000002821 scintillation proximity assay Methods 0.000 description 4
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 4
- KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 3
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960004704 dihydroergotamine Drugs 0.000 description 3
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 238000000611 regression analysis Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- 230000007480 spreading Effects 0.000 description 3
- 238000003892 spreading Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ASXGJMSKWNBENU-CQSZACIVSA-N (7R)-7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound C1=CC(O)=C2C[C@H](N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-CQSZACIVSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000006561 Cluster Headache Diseases 0.000 description 2
- 206010015866 Extravasation Diseases 0.000 description 2
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101150050738 HTR1B gene Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000000060 Migraine with aura Diseases 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 101150037263 PIP2 gene Proteins 0.000 description 2
- 101100262439 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBA2 gene Proteins 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 102000036109 cAMP binding proteins Human genes 0.000 description 2
- 108091010966 cAMP binding proteins Proteins 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 208000018912 cluster headache syndrome Diseases 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960003133 ergot alkaloid Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000036251 extravasation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 108700025906 fos Genes Proteins 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960001186 methysergide Drugs 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000009117 preventive therapy Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 230000002295 serotoninergic effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000000427 trigeminal ganglion Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- WKZLNEWVIAGNAW-DOMYTETQSA-N 3-(2-amino-1,1,2,2-tetratritioethyl)-1h-indole-5-carboxamide Chemical compound C1=C(C(N)=O)C=C2C(C([3H])([3H])C([3H])(N)[3H])=CNC2=C1 WKZLNEWVIAGNAW-DOMYTETQSA-N 0.000 description 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
- 101710138085 5-hydroxytryptamine receptor 1E Proteins 0.000 description 1
- 102100036312 5-hydroxytryptamine receptor 1E Human genes 0.000 description 1
- 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 description 1
- 101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 description 1
- 102100040370 5-hydroxytryptamine receptor 5A Human genes 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000017911 HTR1A Human genes 0.000 description 1
- 101150015707 HTR1A gene Proteins 0.000 description 1
- 101150049624 HTR5A gene Proteins 0.000 description 1
- 108010077223 Homer Scaffolding Proteins Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 101150087850 Htr5b gene Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 239000012839 Krebs-Henseleit buffer Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- AWEZYKMQFAUBTD-UHFFFAOYSA-N Naratriptan hydrochloride Chemical compound [H+].[Cl-].C12=CC(CCS(=O)(=O)NC)=CC=C2NC=C1C1CCN(C)CC1 AWEZYKMQFAUBTD-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000005056 Ophthalmoplegic Migraine Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100024304 Protachykinin-1 Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 206010038776 Retching Diseases 0.000 description 1
- 241000144290 Sigmodon hispidus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical group C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004781 brain capillary Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
- 229960000326 flunarizine Drugs 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- AFJSFHAKSSWOKG-UHFFFAOYSA-N hydron;n-[1-[2-(1h-indol-3-yl)ethyl]piperidin-4-yl]benzamide;chloride Chemical compound Cl.C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1 AFJSFHAKSSWOKG-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical group CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000006959 non-competitive inhibition Effects 0.000 description 1
- 229940121367 non-opioid analgesics Drugs 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- FIADGNVRKBPQEU-UHFFFAOYSA-N pizotifen Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 FIADGNVRKBPQEU-UHFFFAOYSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- LZFIOSVZIQOVFW-UHFFFAOYSA-N propyl 2-hydroxybenzoate Chemical class CCCOC(=O)C1=CC=CC=C1O LZFIOSVZIQOVFW-UHFFFAOYSA-N 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000007398 protein translocation Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 239000002331 radioactive microsphere Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 108010053303 serotonin 1F receptor Proteins 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 208000027765 speech disease Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- HHLJUSLZGFYWKW-UHFFFAOYSA-N triethanolamine hydrochloride Chemical compound Cl.OCCN(CCO)CCO HHLJUSLZGFYWKW-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940063674 voltaren Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- ULSDMUVEXKOYBU-ZDUSSCGKSA-N zolmitriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1C[C@H]1COC(=O)N1 ULSDMUVEXKOYBU-ZDUSSCGKSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to selective binding partners for 5-HT5-receptors, methods, in particular screening methods, for identifying and characterizing such binding partners, as well as pharmaceutical compositions containing said binding partners and their use in the treatment of cerebrovascular diseases such as migraine.
Description
IN VITRO SCREENING METHOD FOR IDENTIFYING SELECTIVE BINDING
FIELD OF THE INVENTION
The present invention relates to binding partners for 5-HT5 receptors, processes for the identification and characterization of binding partners of this type, and also pharmaceutical compositions comprising them and their use for the treatment of cerebrovascular disorders such as migraine.
BACKGROUND
At least seven different receptor classes mediate the manifold physiological activities which are ascribed to an involvement of the neurotransmitter serotonin (5-hydroxytryptamine, abbreviated 5-HT). According to an internationally recognized classification, they are designated by 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6 and 5-HT7. Most of these classes moreover include receptor types which can be differentiated further. Thus the 5-HT1 class includes receptors which can be divided into at least five subclasses, which are designated by 5-HT1A, 5-HT1B, 5-HT1C, 5-HT1D and 5-HT1E (Boess F.G. and Martin I.L., Neuropharmacology 33:275-317 (1994)).
The 5-HT5 class was described for the first time by Plassat et al., The EMBO Journal Vol. 11 No. 13, pp. 4779-4786 (1992).
5-HT5A and 5-HT5B receptors are differentiated (Erlander et al., Proc. Natl. Acad. Sci. USA 90:3452-3456 (1993)). Only small sequence homologies exist between 5-HT5 and other 5-HT receptors.
The pharmacological profile of these receptors differs markedly.
Using molecular biology techniques, the localization of 5-HT5 receptors was possible in the olfactory bulb, in the hippocampus, in the cortex, in the cerebral ventricles, in the corpus callosum and in the cerebellum. By means of immunohistochemical methods, it was possible to show that 5-HT5 receptors are principally expressed on astrocytes (Carson et al., GLIA 17:317-326 (1996)).
Astrocytes are directly adjacent to the basal membrane of brain capillaries of the blood-brain barrier. An abnormal astrocyte endothelium structure accompanies; a loss of the blood-brain barrier. The exact significance of the astrocytes is unclear.
They appear to carry out transport tasks and connective functions. Reactive astrocytes were observed in connection with reactive gliosis in a number of pathological brain changes and neuropsychiatric disorders. As a result of brain injuries, they change their morphologies. The protein expression pattern changes la and growth factors are produced. in vitro investigations on cultured astrocytes have allowed the detection of 5-HT5 receptor-mediated responses. It is thus to be suspected on the one hand that they are involved in recovery processes of the brain after disorders, but on the other hand it is also not to be excluded that they contribute to the creation of damage or even to an increase in damage.
Migraine is a CNS disorder which affects large parts of the population. In most cases, it is manifested by headaches which recur again and again, by which, at a rough estimate, 8 million people, i.e. 3-5% of all children, 7% of all men and 14% of all women, are affected. Even though a genetic predisposition is propagated, the causes appear to be complex (Diener H.C. et al., Arzneimitteltherapie 15:387-394 (1997)).
Two hypotheses are dominant. The already long-known vascular theory proposes as a cause a dilatation process of the internal and external cerebral vascular system. The neurogenic theory is based on secretion of vasoactive neurotransmitters, principally neuropeptides, such as substance P and neurokinin, from axons of the vasculature as a result of stimulation of certain ganglia which innervate brain tissue, and which should lead to inflammatory reactions and thus to pain.
At present, there is still no causal therapy for the treatment of migraine. Two different treatment methods are used at present, a first, prophylactic therapy for the prevention of recurring migraine attacks and a second, symptomatic therapy for the suppression of acute symptoms during attacks. Migraine-specific active compounds, such as Sanmigran , Nocerton , Desernil and Vidora , but also active compounds'usually used for other indications, such as beta-blockers, antiemetic active compounds, such as Sibelium , antidepressants such as Laroxyl , or antiepileptic active compounds such as Depakin , are administered prophylactically. In the course of acute therapy, analgesics are given, such as aspirin, paracetamol or Optalidon , nonsteroidal antiinflammatories, such as Cebutid , Voltaren , Brufen , Ponstyl , Profenid , Apranx and Naprosin against pain and inflammation, ergot alkaloids, such as ergotamine, dihydroergotamine, which can induce vasoconstriction, or substances of the triptan family, such as sumatriptan, Naramig , and AscoTop having a high affinity for 5-HT1D receptors. The latter substances act as agonists and block vasodilatation.
The active compounds mentioned, however, are not optimally suited for the treatment of migraine. Nonopioid analgesics often have side effects. As a result of the strong peripheral vasoconstriction, the complex mechanism of action of the ergot alkaloids leads to side effects such as hypertension and gangrene. Compounds belonging to the triptan family are also not completely satisfactory (Pfaffenrath V., Munch. med. Wschr.
625-626 (1998))..
Sumatriptan (Imigran ), one of the most effective and most frequently employed active compounds against acute migraine attacks, does not pass through the blood-brain barrier on account of marked hydrophilicity. In 28% of the patients, this active compound is ineffective and the oral doses of 50-100 mg are quite high. Contraindications which have been known are coronary vasospasms, hypertension, kidney and liver disorders.
Up to now, compounds having selective affinity for 5-HT1 receptors have been considered for the treatment of migraine (Goadsby P.J., CNS Drugs 10:271-286 (1998); Saxena P.R., Exp.
Opin. Invest. Drugs 581-593 (1996)). For example, sumatriptan counts as a very selective ligand for 5-HT1D receptors, which is why the professional world are at pains to optimize these binding properties and the vasoconstrictive activities mediated thereby.
The same applies to 5-HT1B and 5-HT1F receptor ligands. Thus, a series of active compounds was developed which, however, were also unable to remedy the problems outlined.
SUMMARY OF THE INVENTION
It is therefore an object of the present invention to make possible the preferably acute tratment of migraine-like cerebrovascular disorders with adequate efficacy and slight side effects.
Surprisingly, it has now been found that substances having comparatively high binding affinity for 5-HT5 receptors can provide the effects desired.
The present invention therefore relates to selective binding partners for 5-HT5 receptors, whose binding affinity for 5-HT5 receptors is greater.than for one or more 5-HT receptors other than 5-HT5.
More specifically, the present invention relates to an in vitro screening process for the identification of compounds for the treatment of migrainous cerebrovascular disorders, which comprises determining the affinity of 3a the compounds for a 5-HT5 receptor, and selecting 5-HT5 binding partners whose binding affinity for the 5-HT5 receptor is at least 10-times greater than their binding affinity for the 5-HT1 D receptor.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 shows a plot of [3H]5-CT bound to h5-HT5 receptor-expressing cells as a function of the 13H]5-CT concentration.
Figure 2 shows the [35 S]GTPyS binding to h5-HT5 receptor-expressing cells induced by 5-HT or S-CT.
Figure 3 shows [35S]GTPyS bound to h5-HT5 receptor-expressing cells as a function of GDP concentration (A) and the stimulation of [35S]GTPyS binding to h5-HT5 receptor-expressing cells as a function of GDP concentration (B).
Figure 4 shows the stimulation of (35S]GTPyS binding to h5-HT5 receptor-expressing cells as a function of 5-HT concentration.
Figure 5 shows intracellular Ca2' concentration as a function of time after stimulation of 5-HT5 receptors with R(+)-lisuride (1 pM) in HEK293 cells.
DETAILED DESCRIPTION OF THE INVENTION
As used herein, the term "binding partner for 5-HT5 receptors" describes substances which bind to 5-HT5 receptors and can therefore also be designated as 5-HT5 receptor Ilgands.
or include metal complex-like coordinative bonds. In addition to the abovementioned, reversible molecular interactions, irreversible interactions between binding partner and receptor can also be possible, such as, for example, covalent bonds.
FIELD OF THE INVENTION
The present invention relates to binding partners for 5-HT5 receptors, processes for the identification and characterization of binding partners of this type, and also pharmaceutical compositions comprising them and their use for the treatment of cerebrovascular disorders such as migraine.
BACKGROUND
At least seven different receptor classes mediate the manifold physiological activities which are ascribed to an involvement of the neurotransmitter serotonin (5-hydroxytryptamine, abbreviated 5-HT). According to an internationally recognized classification, they are designated by 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6 and 5-HT7. Most of these classes moreover include receptor types which can be differentiated further. Thus the 5-HT1 class includes receptors which can be divided into at least five subclasses, which are designated by 5-HT1A, 5-HT1B, 5-HT1C, 5-HT1D and 5-HT1E (Boess F.G. and Martin I.L., Neuropharmacology 33:275-317 (1994)).
The 5-HT5 class was described for the first time by Plassat et al., The EMBO Journal Vol. 11 No. 13, pp. 4779-4786 (1992).
5-HT5A and 5-HT5B receptors are differentiated (Erlander et al., Proc. Natl. Acad. Sci. USA 90:3452-3456 (1993)). Only small sequence homologies exist between 5-HT5 and other 5-HT receptors.
The pharmacological profile of these receptors differs markedly.
Using molecular biology techniques, the localization of 5-HT5 receptors was possible in the olfactory bulb, in the hippocampus, in the cortex, in the cerebral ventricles, in the corpus callosum and in the cerebellum. By means of immunohistochemical methods, it was possible to show that 5-HT5 receptors are principally expressed on astrocytes (Carson et al., GLIA 17:317-326 (1996)).
Astrocytes are directly adjacent to the basal membrane of brain capillaries of the blood-brain barrier. An abnormal astrocyte endothelium structure accompanies; a loss of the blood-brain barrier. The exact significance of the astrocytes is unclear.
They appear to carry out transport tasks and connective functions. Reactive astrocytes were observed in connection with reactive gliosis in a number of pathological brain changes and neuropsychiatric disorders. As a result of brain injuries, they change their morphologies. The protein expression pattern changes la and growth factors are produced. in vitro investigations on cultured astrocytes have allowed the detection of 5-HT5 receptor-mediated responses. It is thus to be suspected on the one hand that they are involved in recovery processes of the brain after disorders, but on the other hand it is also not to be excluded that they contribute to the creation of damage or even to an increase in damage.
Migraine is a CNS disorder which affects large parts of the population. In most cases, it is manifested by headaches which recur again and again, by which, at a rough estimate, 8 million people, i.e. 3-5% of all children, 7% of all men and 14% of all women, are affected. Even though a genetic predisposition is propagated, the causes appear to be complex (Diener H.C. et al., Arzneimitteltherapie 15:387-394 (1997)).
Two hypotheses are dominant. The already long-known vascular theory proposes as a cause a dilatation process of the internal and external cerebral vascular system. The neurogenic theory is based on secretion of vasoactive neurotransmitters, principally neuropeptides, such as substance P and neurokinin, from axons of the vasculature as a result of stimulation of certain ganglia which innervate brain tissue, and which should lead to inflammatory reactions and thus to pain.
At present, there is still no causal therapy for the treatment of migraine. Two different treatment methods are used at present, a first, prophylactic therapy for the prevention of recurring migraine attacks and a second, symptomatic therapy for the suppression of acute symptoms during attacks. Migraine-specific active compounds, such as Sanmigran , Nocerton , Desernil and Vidora , but also active compounds'usually used for other indications, such as beta-blockers, antiemetic active compounds, such as Sibelium , antidepressants such as Laroxyl , or antiepileptic active compounds such as Depakin , are administered prophylactically. In the course of acute therapy, analgesics are given, such as aspirin, paracetamol or Optalidon , nonsteroidal antiinflammatories, such as Cebutid , Voltaren , Brufen , Ponstyl , Profenid , Apranx and Naprosin against pain and inflammation, ergot alkaloids, such as ergotamine, dihydroergotamine, which can induce vasoconstriction, or substances of the triptan family, such as sumatriptan, Naramig , and AscoTop having a high affinity for 5-HT1D receptors. The latter substances act as agonists and block vasodilatation.
The active compounds mentioned, however, are not optimally suited for the treatment of migraine. Nonopioid analgesics often have side effects. As a result of the strong peripheral vasoconstriction, the complex mechanism of action of the ergot alkaloids leads to side effects such as hypertension and gangrene. Compounds belonging to the triptan family are also not completely satisfactory (Pfaffenrath V., Munch. med. Wschr.
625-626 (1998))..
Sumatriptan (Imigran ), one of the most effective and most frequently employed active compounds against acute migraine attacks, does not pass through the blood-brain barrier on account of marked hydrophilicity. In 28% of the patients, this active compound is ineffective and the oral doses of 50-100 mg are quite high. Contraindications which have been known are coronary vasospasms, hypertension, kidney and liver disorders.
Up to now, compounds having selective affinity for 5-HT1 receptors have been considered for the treatment of migraine (Goadsby P.J., CNS Drugs 10:271-286 (1998); Saxena P.R., Exp.
Opin. Invest. Drugs 581-593 (1996)). For example, sumatriptan counts as a very selective ligand for 5-HT1D receptors, which is why the professional world are at pains to optimize these binding properties and the vasoconstrictive activities mediated thereby.
The same applies to 5-HT1B and 5-HT1F receptor ligands. Thus, a series of active compounds was developed which, however, were also unable to remedy the problems outlined.
SUMMARY OF THE INVENTION
It is therefore an object of the present invention to make possible the preferably acute tratment of migraine-like cerebrovascular disorders with adequate efficacy and slight side effects.
Surprisingly, it has now been found that substances having comparatively high binding affinity for 5-HT5 receptors can provide the effects desired.
The present invention therefore relates to selective binding partners for 5-HT5 receptors, whose binding affinity for 5-HT5 receptors is greater.than for one or more 5-HT receptors other than 5-HT5.
More specifically, the present invention relates to an in vitro screening process for the identification of compounds for the treatment of migrainous cerebrovascular disorders, which comprises determining the affinity of 3a the compounds for a 5-HT5 receptor, and selecting 5-HT5 binding partners whose binding affinity for the 5-HT5 receptor is at least 10-times greater than their binding affinity for the 5-HT1 D receptor.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 shows a plot of [3H]5-CT bound to h5-HT5 receptor-expressing cells as a function of the 13H]5-CT concentration.
Figure 2 shows the [35 S]GTPyS binding to h5-HT5 receptor-expressing cells induced by 5-HT or S-CT.
Figure 3 shows [35S]GTPyS bound to h5-HT5 receptor-expressing cells as a function of GDP concentration (A) and the stimulation of [35S]GTPyS binding to h5-HT5 receptor-expressing cells as a function of GDP concentration (B).
Figure 4 shows the stimulation of (35S]GTPyS binding to h5-HT5 receptor-expressing cells as a function of 5-HT concentration.
Figure 5 shows intracellular Ca2' concentration as a function of time after stimulation of 5-HT5 receptors with R(+)-lisuride (1 pM) in HEK293 cells.
DETAILED DESCRIPTION OF THE INVENTION
As used herein, the term "binding partner for 5-HT5 receptors" describes substances which bind to 5-HT5 receptors and can therefore also be designated as 5-HT5 receptor Ilgands.
or include metal complex-like coordinative bonds. In addition to the abovementioned, reversible molecular interactions, irreversible interactions between binding partner and receptor can also be possible, such as, for example, covalent bonds.
Selectivity is understood as meaning the property of a binding partner to bind preferably to 5-HT5 receptors.
Thus binding partners have binding affinities for 5-HT5 receptors which are greater than for one or more 5-HT receptors other than 5-HT5, i.e. in particular receptors to be assigned to the abovementioned 5-HT receptor classes 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT6 and 5-HT7. If the binding affinity for 5-HT5 receptors of a binding partner is greater than that of a 5-HT receptor other than 5-HT5, in relation to the 5-HT receptor which is other than 5-HT5 a more selective binding of these binding partners to 5-HT5 receptors is referred to. Particular binding partners are those whose binding affinity for 5-HT5 receptors is greater than for at least one and, in particular, all 5-HT1 receptors, in particular for 5-HT1D and/or 5-HT1B receptors. Binding partners whose binding affinity for 5-HT5 receptors is greater than for all 5-HT
receptors other than 5-HT5 are a further particular class of binding partners according to the invention.
It is decisive for the selectivity outlined above that the binding affinities for 5-HT5 receptors, on the one hand, and for one or more 5-HT receptors other than 5-HT5, on the other hand, differ sufficiently. Affinity differences are preferred whereby binding affinity ratios of at least 2, more advantageously of at least 5, particularly advantageously of at least 10, preferably of at least 20, particularly preferably of at least 50 and in particular of at least 100, are present.
According to one embodiment, binding partners according to the invention competitively inhibit the binding of comparison binding partners, such as 5-HT (5-hydroxytryptamine) or 5-CT
(5-carboxamidotryptamine), to 5-HT5 receptors.
Competitive inhibition is understood as meaning that binding partners according to the invention compete with a comparison binding partner, in the present, case for example, 5-HT or 5-CT, for binding to the receptor, i.e. the binding of one prevents the binding of the other.
According to a further embodiment, binding partners according to the invention inhibit the binding of comparison binding partners, such as 5-HT (5-hydroxytryptamine) or 5-CT (5-carboxamido-tryptamine), to 5-HT5 receptors noncompetitively.
Noncompetitive inhibition is understood as meaning that binding partners according to the invention modulate the binding of a comparison binding partner, in the present case, for example, 5-HT or 5-CT, in particular decrease its binding affinity, via their binding to the receptor.
At least in the case of competitive inhibition, i.e. of 5 reversible binding, the principle applies that the displacement of one binding partner by another increases with decreasing binding affinity of the one or increasing binding affinity of the other with respect to the receptor. More expediently, therefore, binding partners which can be used according to the invention have a high binding affinity for 5-HT5 receptors. A binding affinity of this type allows, on the one hand, an effective displacement of naturally occurring binding partners for 5-HT5 receptors, such as, for example, serotonin (5-hydroxytryptamine, 5-HT) itself, where the necessary concentration of binding partners which can be used according to the invention for the binding of a certain amount of this binding partner to 5-HT5 receptors decreases with increasing binding affinity. With respect to medical use, binding partners are therefore preferred whose binding affinity is so great that these can be administered in justifiable amounts in the course of an effective medical treatment as an active compound. Binding partners according to the invention are therefore preferably administered in daily doses of approximately 0.01 to 100 mg/kg of body weight and in particular of approximately 0.1 to 15 mg/kg of body weight on parenteral administration and 1 to 30 mg/kg of body weight on oral administration.
The competition experiments referred to above, with which that concentration of binding partner according to the invention is determined in vitro which displaces 50% of another comparison binding partner from the receptor binding site (ICSO values), offer one possibility of expressing the binding affinity. Thus the competitive inhibition of the binding of 5-CT to 5-HT5 receptors can also be evaluated to the effect that binding partners which can preferably be used according to the invention have half-maximal inhibition constants IC50 of less than 10-7 M, preferably of less than 10-8 M and in particular of less than 10-9 M.
The binding affinity of binding partners according to the invention can also be expressed by means of the inhibition constant Ki, which is in general likewise determined in vitro using competition experiments. For the binding of 5-HT5 receptors, binding partners according to the invention preferably have Ki values of less than 10-8 M, advantageously of less than 10-9 M and particularly preferably of less than 10-10 M. Ki values of compounds according to the invention are, for example, in the range from 1.10-7 M to 7.10-7 M or in the range from 1.10-8 M to 1.10-7 M.
According to a further embodiment, binding partners according to the invention bind more selectively to 5-HT5 receptors having the advantageous binding affinities described above in relation to one or more 5-HT receptors other than 5-HT5.
According to a further embodiment, binding partners according to the invention bind more selectively to 5-HT5 receptors having the advantageous binding affinities described above in relation to all 5-HT receptors other than 5-HT5.
Binding partners are particularly advantageous which bind to 5-HT5 receptors which are expressed by glia cells and in particular by astrocytes with the affinities and selectivities described above.
According to the invention, the human receptor variant is a preferred target for the binding partners employed according to the invention.
The binding of binding partners according to the invention to 5-HT5 receptors is coupled to an effector function. Binding partners can act agonistically or antagonistically and partly agonistically and/or partly antagonistically.
Agonists are designated as compounds according to the invention which completely or partially imitate the activity of 5-HT on 5-HT5 receptors.
Agonists are designated as compounds according to the invention which can block the agonistic activity of 5-HT on 5-HT5 receptors.
According to a particular embodiment of the present invention, 5-HT5 agonists are provided as binding partners. The expression "5-HT5 agonist" designates binding partners which induce a partly to fully agonistic action. A binding partner which induces a partly agonistic action at the 5-HT5 receptor has sufficiently agonistic activity according to the invention in order to be able to be administered in justifiable amounts in the course of an efficacious medical treatment. Preferred binding partners in the context of this embodiment are those having at least 50%
agonistic action. Particularly preferred binding partners are those having at least 80% agonistic action and in particular those having essentially fully agonistic action (Emax).
According to a particular embodiment of the present invention, binding partners are made available whose binding, at least to 5-HT5 receptors of h5-HT5-transfected CHO cells, brings about a stimulation of the GTP binding to membrane-bound G proteins, an agonist-induced change in intracellular calcium levels, an induction of phospholipase C activity and/or an agonist-induced change in cAMP production. As far as the change in intracellular calcium levels is concerned, the use of binding partners which bring about an increase in intracellular calcium levels is a particular embodiment of the invention.
This embodiment also includes binding partners which are active in known animal models of cerebrovascular disorders, in particular for migraine, and/or which induce certain in vivo actions in areas of the brain, in particular genomic responses in the brain, for example the expression of transcription factors such as c-fos, c-jun, zif268 or Homer gene isoforms (Brakeman P.R. et al., Nature 386:284-288 (1997)).
Preferred binding partners are those which, also with respect to their effector function, are selective in the sense described above for 5-HT5 receptors.
According to one embodiment, 5-HT5 binding partners are low molecular weight, usually synthetic compounds.
According to a further embodiment, 5-HT5 binding partners according to the invention are 5-HT5-specific antibodies. They can be polyclonal antisera, monoclonal antibodies, antibody fragments, such as F(ab), Fc, etc., chimeric and recombinant antibodies. Such antibodies can be prepared in a manner known per se. The immunogen used can be a 5-HT5 receptor as such or antigenic fragments, as a rule fragments coupled to customary carrier proteins.
According to a further embodiment, 5-HT5 binding partners according to the invention are aptamers, i.e. nucleic acids, as a rule oligonucleotides, having sufficient affinity for 5-HT5 receptors.
Assays for the determination of binding affinities of binding partners according to the invention to 5-HT5 receptors are known in principle. This can be carried out, for example, by assessing the competitive inhibition of the binding of a comparison binding partner to 5-HT5 receptors by the substance to be investigated.
Suitable comparison binding partners are known ligands for 5-HT
receptors, such as 5-HT or 5-CT or LSD. These are expediently labeled such that their binding to 5-HT receptors can be monitored analytically using standard methods. Radioactive and optical labels are preferred. In the case of binding studies on 5-HT5 receptors, 5-CT or LSD, in particular in the form of [3Hj-LSD, is used according to the invention. The binding affinities can be expressed as the half-maximal inhibition constant IC50 or as the inhibition constant Ki. This process is preferably used for primary screening. SPA or FlashPlate technology is preferably used.
The binding to binding partners to be investigated can also be determined directly on 5-HT receptors. The inhibition constants Ki expressing binding affinity can be determined, for example, calorimetrically, i.e. by measurement of the binding energy released.
For the determination of selectivities, the binding affinity of the binding partners to be investigated for other 5-HT receptors is determined in the same manner - if appropriate using the ligands specific for the respective receptor - and the values obtained are compared.
Effector functions can also be assessed qualitatively or quantitatively both in vitro and in vivo with the aid of known functional assays.
The assessment of an agonistic activity can be based on all those effects which are caused by the binding of 5-HT to 5-HT5 receptors. It is preferred according to the invention to assess the actions on the binding of GTP to G proteins on intercellular calcium levels, on phospholipase C activity and/or on cAMP
production. These processes are preferably used for secondary screening. Here too, SPA or FlashPlate technology is advantageously used.
The GTP binding to G proteins can be investigated by using a nonhydrolyzable analog of GTP, for example [35S]GTPyS, whose binding can be investigated radiologically. This investigation is preferably carried out on membranes having a 5-HT5 receptor.
For the measurement of intracellular calcium levels, suitable calcium probes, as a rule calcium chelators, for example fluorescent compounds, such as Fura 2-acetylmethyl ester or Fluo-3-AM, can be employed. This investigation is preferably carried out in cell cultures having a 5-HT5 receptor, in particular in individual cells.
The phospholipase C activity can be determined by means of its catalytic reactions, for example the incorporation of myoinositol, which for detection purposes is preferably radiolabeled as [3H]-myoinositol, or the reaction of PPIPZ to IP3, the PPIP2 preferably also being radiolabeled as (32P]PIP2. These investigations are preferably carried out on individual cells having a 5-HT5 receptor.
The cAMP production can be determined with the aid of the cAMP
binding protein. This investigation is preferably carried out on individual cells having a 5-HT5 receptor.
If appropriate, the effector function is also determined, i.e.
the activity of binding partners according to the invention for other 5-HT receptors. This is expediently carried out taking into consideration the binding affinities determined for 5-HT5 and other 5-HT receptors, i.e. in particular taking into consideration the selectivity.
The present invention therefore also relates to processes for the identification and characterization of binding partners according to the invention. These and further similarly suitable processes .can form the basis for in vitro screening processes, with which it is possible to select from a large number of different compounds those which appear to be most promising with respect to future use. For example, it is possible by means of combinatorial chemistry to set up extensive substance banks which comprise myriads of potential active compounds. The scrutinizing of combinatorial substance libraries for substances with the desired activity can be automated. Screening robots are used for the efficient analysis of the individual assays, which are preferably organized on microtiter plates. Thus the present invention also relates to screening processes, i.e. both primary and secondary screening processes, in which preferably at least one of the processes described below is used. If a number of processes are used, this can take place at different times or at the same time on one and the same sample or on different samples of a substance to be investigated.
A particularly effective technology for carrying out processes of this type is the scintillation proximity assay, called SPA for short, which is known in the field of active compound screening.
Kits and components for carrying out this assay can be obtained commercially, for example from Amersham Pharmacia Biotech. In principle, solubilized or membrane-bound receptors are immobilized on small fluoromicrospheres containing scintillator.
If, for example, a radioligand binds to the immobilized receptors, the scintillator is stimulated to emit light, as the 5 spatial proximity between scintillator and radioligand is afforded.
A further particularly effective technology for carrying out processes of this type is the FlashPlate technology known in the 10 field of active compound screening. Kits and components for carrying out this assay can be obtained commercially, for example from NEN Life Science Products. This principle is likewise based on microtiter plates (96-well or 384-well) which are coated with scintillator.
The abovementioned assays are known in principle to the person skilled in the art.
A first process according to the invention is used for the determination of the affinity and/or selectivity of binding partners for 5-HT5 receptors. For this purpose, the binding partner is brought into contact with 5-HT5 receptors and the binding affinity is determined.
A further process according to the invention relates to the determination of the activity of binding partners for 5-HT5 receptors, i.e. the determination of agonistic, partly agonistic, antagonistic and/or partly antagonistic action. For this purpose, the binding partner is brought into contact with 5-HT5 receptors and the effects produced by the binding are assessed.
According to a preferred embodiment, binding partners are subjected to a primary screening by determining their binding affinity to 5-HT5 receptors using the [3HJ-5-CT or 13H]-LSD
competition experiment described above. Those binding partners which have an inhibition constant IC50 in the range of 10-6 M or less are then subjected to a secondary screening by assessing their effector function in the manner described above, in particular with respect to GTP binding and/or the intracellular calcium levels. Finally, the binding partners selected in this way are subjected to a counter-screening for selectivity determination by determining their binding affinity to further 5-HT receptors essentially in the manner described above - but optionally using the ligands specific to the respective receptor.
For example, [3H]-8-hydroxydipropylaminotetralin ([3H]-8-DPAT) can be used for binding studies to 5-HT1A receptors, while 5-HT1B and 5-HT1D receptors can be investigated using [3H]-5-CT.
5-HT5 receptors are preferably made available in the form of cellular systems, i.e. in the form of membranes, cells, cell colonies, tissues or organs which carry 5-HT5 receptors. Cellular systems of this type can express 5-HT5 receptors by nature, but they can also be induced to express 5-HT5 by suitable genetic manipulation, e.g. by transfection. In the context of the preferred embodiment of the present invention concerning h5-HT5, the coding sequence described in Rees S. et al, FEBS Letters 335:242-246 (1994) can in particular be used for this (accession number X81411). Human glioma cell lines are preferred as natural cellular systems having 5-HT5 receptors. Of the h5-HT5-transfected heterologous cell lines, those are preferred which express the h5-HT5 gene. Mention may be made, for example, of h5-HT5-transfected CHO cells, h5-HT5-transfected human kidney cells, in particular h5-HT5-transfected HEK293 cells, or h5-HT5-transfected C-6 glioma cells.
For the determination of selectivity, affinity and activity of binding partners according to the invention, it is also possible to use brain tissue sections and native membranes from brain parts. if radiolabels are employed, the assessment of tissue sections is preferably carried out autoradiographically.
The efficacy of binding partners according to the invention for the treatment of migraine is preferably determined on animal models which base on mechanisms which can underlie the formation of migraine.
For example, the protein extravasation induced by binding partners according to the invention can be determined. This assay can be carried out in a manner known per se, for example by using fluorescence staining (Johnson K.W. and Phebus L.A. (1998) J.
Neurosci. Methods 81: 19-24) or isotopically labeled albumin (Petty M.A. et al., (1997) Eur. J. Pharmacol. 336: 127-136). For this, the animals are treated in succession with the test compound and with (125I]-albumin or fluorescent dye. The trigeminal ganglion is then electrically stimulated. The radioactivity or fluorescence accumulated in the dura mater is determined. The antimigraine activity of binding partners according to the invention is seen in the protein extravasation induced by stimulation of trigeminal ganglia.
Thus binding partners have binding affinities for 5-HT5 receptors which are greater than for one or more 5-HT receptors other than 5-HT5, i.e. in particular receptors to be assigned to the abovementioned 5-HT receptor classes 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT6 and 5-HT7. If the binding affinity for 5-HT5 receptors of a binding partner is greater than that of a 5-HT receptor other than 5-HT5, in relation to the 5-HT receptor which is other than 5-HT5 a more selective binding of these binding partners to 5-HT5 receptors is referred to. Particular binding partners are those whose binding affinity for 5-HT5 receptors is greater than for at least one and, in particular, all 5-HT1 receptors, in particular for 5-HT1D and/or 5-HT1B receptors. Binding partners whose binding affinity for 5-HT5 receptors is greater than for all 5-HT
receptors other than 5-HT5 are a further particular class of binding partners according to the invention.
It is decisive for the selectivity outlined above that the binding affinities for 5-HT5 receptors, on the one hand, and for one or more 5-HT receptors other than 5-HT5, on the other hand, differ sufficiently. Affinity differences are preferred whereby binding affinity ratios of at least 2, more advantageously of at least 5, particularly advantageously of at least 10, preferably of at least 20, particularly preferably of at least 50 and in particular of at least 100, are present.
According to one embodiment, binding partners according to the invention competitively inhibit the binding of comparison binding partners, such as 5-HT (5-hydroxytryptamine) or 5-CT
(5-carboxamidotryptamine), to 5-HT5 receptors.
Competitive inhibition is understood as meaning that binding partners according to the invention compete with a comparison binding partner, in the present, case for example, 5-HT or 5-CT, for binding to the receptor, i.e. the binding of one prevents the binding of the other.
According to a further embodiment, binding partners according to the invention inhibit the binding of comparison binding partners, such as 5-HT (5-hydroxytryptamine) or 5-CT (5-carboxamido-tryptamine), to 5-HT5 receptors noncompetitively.
Noncompetitive inhibition is understood as meaning that binding partners according to the invention modulate the binding of a comparison binding partner, in the present case, for example, 5-HT or 5-CT, in particular decrease its binding affinity, via their binding to the receptor.
At least in the case of competitive inhibition, i.e. of 5 reversible binding, the principle applies that the displacement of one binding partner by another increases with decreasing binding affinity of the one or increasing binding affinity of the other with respect to the receptor. More expediently, therefore, binding partners which can be used according to the invention have a high binding affinity for 5-HT5 receptors. A binding affinity of this type allows, on the one hand, an effective displacement of naturally occurring binding partners for 5-HT5 receptors, such as, for example, serotonin (5-hydroxytryptamine, 5-HT) itself, where the necessary concentration of binding partners which can be used according to the invention for the binding of a certain amount of this binding partner to 5-HT5 receptors decreases with increasing binding affinity. With respect to medical use, binding partners are therefore preferred whose binding affinity is so great that these can be administered in justifiable amounts in the course of an effective medical treatment as an active compound. Binding partners according to the invention are therefore preferably administered in daily doses of approximately 0.01 to 100 mg/kg of body weight and in particular of approximately 0.1 to 15 mg/kg of body weight on parenteral administration and 1 to 30 mg/kg of body weight on oral administration.
The competition experiments referred to above, with which that concentration of binding partner according to the invention is determined in vitro which displaces 50% of another comparison binding partner from the receptor binding site (ICSO values), offer one possibility of expressing the binding affinity. Thus the competitive inhibition of the binding of 5-CT to 5-HT5 receptors can also be evaluated to the effect that binding partners which can preferably be used according to the invention have half-maximal inhibition constants IC50 of less than 10-7 M, preferably of less than 10-8 M and in particular of less than 10-9 M.
The binding affinity of binding partners according to the invention can also be expressed by means of the inhibition constant Ki, which is in general likewise determined in vitro using competition experiments. For the binding of 5-HT5 receptors, binding partners according to the invention preferably have Ki values of less than 10-8 M, advantageously of less than 10-9 M and particularly preferably of less than 10-10 M. Ki values of compounds according to the invention are, for example, in the range from 1.10-7 M to 7.10-7 M or in the range from 1.10-8 M to 1.10-7 M.
According to a further embodiment, binding partners according to the invention bind more selectively to 5-HT5 receptors having the advantageous binding affinities described above in relation to one or more 5-HT receptors other than 5-HT5.
According to a further embodiment, binding partners according to the invention bind more selectively to 5-HT5 receptors having the advantageous binding affinities described above in relation to all 5-HT receptors other than 5-HT5.
Binding partners are particularly advantageous which bind to 5-HT5 receptors which are expressed by glia cells and in particular by astrocytes with the affinities and selectivities described above.
According to the invention, the human receptor variant is a preferred target for the binding partners employed according to the invention.
The binding of binding partners according to the invention to 5-HT5 receptors is coupled to an effector function. Binding partners can act agonistically or antagonistically and partly agonistically and/or partly antagonistically.
Agonists are designated as compounds according to the invention which completely or partially imitate the activity of 5-HT on 5-HT5 receptors.
Agonists are designated as compounds according to the invention which can block the agonistic activity of 5-HT on 5-HT5 receptors.
According to a particular embodiment of the present invention, 5-HT5 agonists are provided as binding partners. The expression "5-HT5 agonist" designates binding partners which induce a partly to fully agonistic action. A binding partner which induces a partly agonistic action at the 5-HT5 receptor has sufficiently agonistic activity according to the invention in order to be able to be administered in justifiable amounts in the course of an efficacious medical treatment. Preferred binding partners in the context of this embodiment are those having at least 50%
agonistic action. Particularly preferred binding partners are those having at least 80% agonistic action and in particular those having essentially fully agonistic action (Emax).
According to a particular embodiment of the present invention, binding partners are made available whose binding, at least to 5-HT5 receptors of h5-HT5-transfected CHO cells, brings about a stimulation of the GTP binding to membrane-bound G proteins, an agonist-induced change in intracellular calcium levels, an induction of phospholipase C activity and/or an agonist-induced change in cAMP production. As far as the change in intracellular calcium levels is concerned, the use of binding partners which bring about an increase in intracellular calcium levels is a particular embodiment of the invention.
This embodiment also includes binding partners which are active in known animal models of cerebrovascular disorders, in particular for migraine, and/or which induce certain in vivo actions in areas of the brain, in particular genomic responses in the brain, for example the expression of transcription factors such as c-fos, c-jun, zif268 or Homer gene isoforms (Brakeman P.R. et al., Nature 386:284-288 (1997)).
Preferred binding partners are those which, also with respect to their effector function, are selective in the sense described above for 5-HT5 receptors.
According to one embodiment, 5-HT5 binding partners are low molecular weight, usually synthetic compounds.
According to a further embodiment, 5-HT5 binding partners according to the invention are 5-HT5-specific antibodies. They can be polyclonal antisera, monoclonal antibodies, antibody fragments, such as F(ab), Fc, etc., chimeric and recombinant antibodies. Such antibodies can be prepared in a manner known per se. The immunogen used can be a 5-HT5 receptor as such or antigenic fragments, as a rule fragments coupled to customary carrier proteins.
According to a further embodiment, 5-HT5 binding partners according to the invention are aptamers, i.e. nucleic acids, as a rule oligonucleotides, having sufficient affinity for 5-HT5 receptors.
Assays for the determination of binding affinities of binding partners according to the invention to 5-HT5 receptors are known in principle. This can be carried out, for example, by assessing the competitive inhibition of the binding of a comparison binding partner to 5-HT5 receptors by the substance to be investigated.
Suitable comparison binding partners are known ligands for 5-HT
receptors, such as 5-HT or 5-CT or LSD. These are expediently labeled such that their binding to 5-HT receptors can be monitored analytically using standard methods. Radioactive and optical labels are preferred. In the case of binding studies on 5-HT5 receptors, 5-CT or LSD, in particular in the form of [3Hj-LSD, is used according to the invention. The binding affinities can be expressed as the half-maximal inhibition constant IC50 or as the inhibition constant Ki. This process is preferably used for primary screening. SPA or FlashPlate technology is preferably used.
The binding to binding partners to be investigated can also be determined directly on 5-HT receptors. The inhibition constants Ki expressing binding affinity can be determined, for example, calorimetrically, i.e. by measurement of the binding energy released.
For the determination of selectivities, the binding affinity of the binding partners to be investigated for other 5-HT receptors is determined in the same manner - if appropriate using the ligands specific for the respective receptor - and the values obtained are compared.
Effector functions can also be assessed qualitatively or quantitatively both in vitro and in vivo with the aid of known functional assays.
The assessment of an agonistic activity can be based on all those effects which are caused by the binding of 5-HT to 5-HT5 receptors. It is preferred according to the invention to assess the actions on the binding of GTP to G proteins on intercellular calcium levels, on phospholipase C activity and/or on cAMP
production. These processes are preferably used for secondary screening. Here too, SPA or FlashPlate technology is advantageously used.
The GTP binding to G proteins can be investigated by using a nonhydrolyzable analog of GTP, for example [35S]GTPyS, whose binding can be investigated radiologically. This investigation is preferably carried out on membranes having a 5-HT5 receptor.
For the measurement of intracellular calcium levels, suitable calcium probes, as a rule calcium chelators, for example fluorescent compounds, such as Fura 2-acetylmethyl ester or Fluo-3-AM, can be employed. This investigation is preferably carried out in cell cultures having a 5-HT5 receptor, in particular in individual cells.
The phospholipase C activity can be determined by means of its catalytic reactions, for example the incorporation of myoinositol, which for detection purposes is preferably radiolabeled as [3H]-myoinositol, or the reaction of PPIPZ to IP3, the PPIP2 preferably also being radiolabeled as (32P]PIP2. These investigations are preferably carried out on individual cells having a 5-HT5 receptor.
The cAMP production can be determined with the aid of the cAMP
binding protein. This investigation is preferably carried out on individual cells having a 5-HT5 receptor.
If appropriate, the effector function is also determined, i.e.
the activity of binding partners according to the invention for other 5-HT receptors. This is expediently carried out taking into consideration the binding affinities determined for 5-HT5 and other 5-HT receptors, i.e. in particular taking into consideration the selectivity.
The present invention therefore also relates to processes for the identification and characterization of binding partners according to the invention. These and further similarly suitable processes .can form the basis for in vitro screening processes, with which it is possible to select from a large number of different compounds those which appear to be most promising with respect to future use. For example, it is possible by means of combinatorial chemistry to set up extensive substance banks which comprise myriads of potential active compounds. The scrutinizing of combinatorial substance libraries for substances with the desired activity can be automated. Screening robots are used for the efficient analysis of the individual assays, which are preferably organized on microtiter plates. Thus the present invention also relates to screening processes, i.e. both primary and secondary screening processes, in which preferably at least one of the processes described below is used. If a number of processes are used, this can take place at different times or at the same time on one and the same sample or on different samples of a substance to be investigated.
A particularly effective technology for carrying out processes of this type is the scintillation proximity assay, called SPA for short, which is known in the field of active compound screening.
Kits and components for carrying out this assay can be obtained commercially, for example from Amersham Pharmacia Biotech. In principle, solubilized or membrane-bound receptors are immobilized on small fluoromicrospheres containing scintillator.
If, for example, a radioligand binds to the immobilized receptors, the scintillator is stimulated to emit light, as the 5 spatial proximity between scintillator and radioligand is afforded.
A further particularly effective technology for carrying out processes of this type is the FlashPlate technology known in the 10 field of active compound screening. Kits and components for carrying out this assay can be obtained commercially, for example from NEN Life Science Products. This principle is likewise based on microtiter plates (96-well or 384-well) which are coated with scintillator.
The abovementioned assays are known in principle to the person skilled in the art.
A first process according to the invention is used for the determination of the affinity and/or selectivity of binding partners for 5-HT5 receptors. For this purpose, the binding partner is brought into contact with 5-HT5 receptors and the binding affinity is determined.
A further process according to the invention relates to the determination of the activity of binding partners for 5-HT5 receptors, i.e. the determination of agonistic, partly agonistic, antagonistic and/or partly antagonistic action. For this purpose, the binding partner is brought into contact with 5-HT5 receptors and the effects produced by the binding are assessed.
According to a preferred embodiment, binding partners are subjected to a primary screening by determining their binding affinity to 5-HT5 receptors using the [3HJ-5-CT or 13H]-LSD
competition experiment described above. Those binding partners which have an inhibition constant IC50 in the range of 10-6 M or less are then subjected to a secondary screening by assessing their effector function in the manner described above, in particular with respect to GTP binding and/or the intracellular calcium levels. Finally, the binding partners selected in this way are subjected to a counter-screening for selectivity determination by determining their binding affinity to further 5-HT receptors essentially in the manner described above - but optionally using the ligands specific to the respective receptor.
For example, [3H]-8-hydroxydipropylaminotetralin ([3H]-8-DPAT) can be used for binding studies to 5-HT1A receptors, while 5-HT1B and 5-HT1D receptors can be investigated using [3H]-5-CT.
5-HT5 receptors are preferably made available in the form of cellular systems, i.e. in the form of membranes, cells, cell colonies, tissues or organs which carry 5-HT5 receptors. Cellular systems of this type can express 5-HT5 receptors by nature, but they can also be induced to express 5-HT5 by suitable genetic manipulation, e.g. by transfection. In the context of the preferred embodiment of the present invention concerning h5-HT5, the coding sequence described in Rees S. et al, FEBS Letters 335:242-246 (1994) can in particular be used for this (accession number X81411). Human glioma cell lines are preferred as natural cellular systems having 5-HT5 receptors. Of the h5-HT5-transfected heterologous cell lines, those are preferred which express the h5-HT5 gene. Mention may be made, for example, of h5-HT5-transfected CHO cells, h5-HT5-transfected human kidney cells, in particular h5-HT5-transfected HEK293 cells, or h5-HT5-transfected C-6 glioma cells.
For the determination of selectivity, affinity and activity of binding partners according to the invention, it is also possible to use brain tissue sections and native membranes from brain parts. if radiolabels are employed, the assessment of tissue sections is preferably carried out autoradiographically.
The efficacy of binding partners according to the invention for the treatment of migraine is preferably determined on animal models which base on mechanisms which can underlie the formation of migraine.
For example, the protein extravasation induced by binding partners according to the invention can be determined. This assay can be carried out in a manner known per se, for example by using fluorescence staining (Johnson K.W. and Phebus L.A. (1998) J.
Neurosci. Methods 81: 19-24) or isotopically labeled albumin (Petty M.A. et al., (1997) Eur. J. Pharmacol. 336: 127-136). For this, the animals are treated in succession with the test compound and with (125I]-albumin or fluorescent dye. The trigeminal ganglion is then electrically stimulated. The radioactivity or fluorescence accumulated in the dura mater is determined. The antimigraine activity of binding partners according to the invention is seen in the protein extravasation induced by stimulation of trigeminal ganglia.
A further model is based on the distribution of the carotid blood flow. This test is also known per se (Saxena P.R. et al., (1998) Eur. J."Pharmacol. 351: 329-339). For this, radioactive microspheres are injected into the carotid. Following a stabilization phase, the animals are treated with a test compound, and the radioactivity accumulated in the brain is determined in a micro-$-counter.
The measurement of the nitroglycerin-induced c-fos gene expression and translocation is also suitable. For this, animals are treated with nitroglycerin and the compound to be tested. The c-fos gene expression and protein translocation in the nucleus is determined using in-situ hybridization or immunohistochemically (Garcia-Ladona F.J. et al., (1994) Mol. Brain Res. 21: 75-84;
Garcia-Ladona F.J. et al., (1997) J. Neurosci. Res 50: 50-61).
Further models are known from Fernandes de Lima V.M. et al.
(1993) Brain Res. 614: 445-51 (Retinal Spreading depression) and from Kawahara N. et al. (1999) Exp. Neurol. 108: 27-36 (Cortical Spreading Depression).
The use according to the invention of 5-HT5 binding partners comprises, in the context of treatment, a process. In this process, an efficacious amount of one or more 5-HT5 binding partners, as a rule formulated according to pharmaceutical and veterinary medical practice, is administered to the individual to be treated, preferably a mammal, in particular a human, productive animal or pet. Whether such a treatment is indicated and in which form it has to take place, depends on the individual case and is subject to medical assessment (diagnosis), the signs, symptoms and/or malfunctions present, risks of developing certain signs, symptoms and/or malfunctions, and additionally includes further factors.
As a rule, the treatment is carried out by single or repeated daily administration, if appropriate together or in alternation with other active compounds or active compound-containing preparations, such that a daily dose of approximately 0.001 g to 10 g, preferably of approximately 0.001 g to approximately 1 g, is administered to an individual to be treated.
The invention also relates to the production of a pharmaceutical agent for the treatment of an individual, preferably a mammal, in particular a human, productive animal or pet.
The measurement of the nitroglycerin-induced c-fos gene expression and translocation is also suitable. For this, animals are treated with nitroglycerin and the compound to be tested. The c-fos gene expression and protein translocation in the nucleus is determined using in-situ hybridization or immunohistochemically (Garcia-Ladona F.J. et al., (1994) Mol. Brain Res. 21: 75-84;
Garcia-Ladona F.J. et al., (1997) J. Neurosci. Res 50: 50-61).
Further models are known from Fernandes de Lima V.M. et al.
(1993) Brain Res. 614: 445-51 (Retinal Spreading depression) and from Kawahara N. et al. (1999) Exp. Neurol. 108: 27-36 (Cortical Spreading Depression).
The use according to the invention of 5-HT5 binding partners comprises, in the context of treatment, a process. In this process, an efficacious amount of one or more 5-HT5 binding partners, as a rule formulated according to pharmaceutical and veterinary medical practice, is administered to the individual to be treated, preferably a mammal, in particular a human, productive animal or pet. Whether such a treatment is indicated and in which form it has to take place, depends on the individual case and is subject to medical assessment (diagnosis), the signs, symptoms and/or malfunctions present, risks of developing certain signs, symptoms and/or malfunctions, and additionally includes further factors.
As a rule, the treatment is carried out by single or repeated daily administration, if appropriate together or in alternation with other active compounds or active compound-containing preparations, such that a daily dose of approximately 0.001 g to 10 g, preferably of approximately 0.001 g to approximately 1 g, is administered to an individual to be treated.
The invention also relates to the production of a pharmaceutical agent for the treatment of an individual, preferably a mammal, in particular a human, productive animal or pet.
The binding partners according to the invention are usually administered in the form of pharmaceutical compositions which comprise a pharmaceutically tolerable excipient with at least one binding partner according to the invention and, if appropriate, further active compounds. These compositions can be administered, for example, by the oral, rectal, transdermal, subcutaneous, intravenous, intramuscular or intranasal route.
Examples of suitable pharmaceutical formulations are solid pharmaceutical forms, such as powders, granules, tablets, pastilles, sachets, cachets, coated tablets, capsules such as hard and soft gelatin capsules, suppositories or vaginal pharmaceutical forms, semisolid pharmaceutical forms, such as ointments, creams, hydrogels, pastes or patches, and also liquid pharmaceutical forms, such as solutions, emulsions, in particular oil-in-water emulsions, suspensions, for example lotions, injection and infusion preparations, eye and ear drops. Implanted delivery devices can also be used for the administration of binding partners according to the invention. In addition, liposomes, microspheres or polymer matrices can also be used.
In the production of the compositions, binding partners according to the invention are usually mixed or diluted with an excipient.
Excipients can be solid, semisolid or liquid materials which are used as a vehicle or medium for the active compound.
Suitable excipients include, for example, lactose, dextrose, sucrose, sorbitol, mannitol, starches, acacia gum, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup and methylcellulose. In addition, the formulations can comprise pharmaceutically acceptable vehicles or customary excipients, such as lubricants, for example tallow, magnesium stearate and mineral oil; wetting agents; emulsifying and suspending agents; preservatives, such as methyl and propyl hydroxybenzoates; antioxidants; antiirritants; chelating agents;
coating auxiliaries; emulsion stabilizers; film-forming agents;
gel-forming agents; flavor-masking agents; flavor corrigents;
resins; hydrocolloids; solvents; solubilizers; neutralizing agents; permeation accelerators; pigments; quaternary ammonium compounds; refatting and superfatting agents; ointment, cream or oil bases; silicone derivatives; spreading auxiliaries;
stabilizers; sterilizing agents; suppository bases; tablet excipients, such as binders, fillers, lubricants, disintegrants or coatings; propellants; drying agents; opacifying agents;
thickeners; waxes; plasticizers; white oils. A relevant embodiment is based on expert knowledge, such as is presented, for example, in Fiedler, H.P., Lexikon der Hilfsstoffe fir Pharmazie, Kosmetik and angrenzende Gebiete [Encyclopedia of excipierits for pharmacy, cosmetics and related areas], 4th Edition, Aulendorf: ECV-Editio-Kantor-Verlag, 1996.
The present invention also relates to the use of a binding partner for 5-HT5 receptors and in particular of the abovementioned particular and preferred embodiments of binding partners according to the invention for the treatment of migrainous cerebrovascular disorders, especially for the treatment of migraine and other vascular-related headaches, in particular paroxysmal headaches of the migraine type. These include the disorders described as simple and as classical migraine without or with concomitant neurological functional disorders, true and atypical migraine, and also more specific disorders of this type, for example, associated migraine, so-called migraine equivalents, digestive migraine, ophthalmic migraine, ophthalmoplegic migraine, migraine rouge, also described as cluster headache (Horton's syndrome) and cervical migraine. Treatment is understood as meaning both prophylactic therapy, in particular prophylaxis against recurring attacks, for example as interval treatment, and treatment in the case of acute symptoms, in particular during the headache phases. Successful treatment leads to a reduction of the intensity of the symptoms, in particular of the headache, of neurological functional disorders, e.g. of visual, sensory, motor disorders and speech disorders, nausea and retching, and/or of the attack frequency.
Acute treatment of migraine with binding partners is preferred.
The invention in particular also relates to the use of the binding partners mentioned for the treatment of those forms of disorders mentioned above in whose formation and/or course 5-HT5 receptors are involved, i.e. disorders which are modulated by a 5-HT5 receptor activity.
The term "disorder" in the sense according to the invention describes anomalies which as a rule are regarded as pathological conditions and can reveal themselves in the form of certain signs, symptoms and/or malfunctions. The treatment according to the invention can be directed at individual disorders, say anomalies or pathological conditions, but also a number of anomalies which are causally connected with one another can be summarized to give patterns, i.e. syndromes, which can be treated according to the invention.
A treatment within the meaning according to the invention comprises not only the treatment of acute or chronic signs, symptoms and/or malfunctions but also a preventive treatment (prophylaxis), in particular as relapse or phase prophylaxis. The treatment can be accomplished symptomatically, for example as symptom-suppression. It can be carried out short-term, be accomplished medium-term, or it can also be a long-term 5 treatment, for example in the context of maintenance therapy.
Binding partners which can be used for migraine treatment can bind to 5-HT5 with a lower, an essentially identical, or a higher affinity than to a specific receptor which is different from 10 5-HT5.
Binding partners for 5-HT5 receptors with respect to the use according to the invention thus in particular include those whose binding affinity for 5-HT5 receptors compared with the affinity 15 for 5-HT1 receptors, in particular 5-HT1B and/or 5-HT1D, is so high that they are advantageously suitable for the use according to the invention. This does not necessarily presuppose a comparatively more selective binding to 5-HT5 receptors, even those selective binding partners for 5-HT5 receptors are a particular embodiment of the present invention.
For example, binding partners can be used which have a high affinity both for 5-HT5 and for 5-HT1 receptors, in particular for 5-HT1B and/or 5-HT1D. High affinity in this connection means Ki values as a rule in the range from 1-10-9 M to 1.10-6 M.
According to a particular embodiment, in the high-affinity range usable binding partners have, relative to 5-HT receptors, a binding profile that is marked by a binding affinity to 5-HT5 which, in comparison with other binding affinities of this range is essentially identical or only slightly less. Factors of 10 or less can be advantageous.
According to a further embodiment of the invention, the selective 5-HT5 binding partners described previously are employed.
According to a particular embodiment of the present invention, binding partners are employed whose binding, at least to 5-HT5 receptors of h5-HT5-transfected CHO cells, brings about a change in the agonist-induced stimulation of the GTP binding to membrane-bound G proteins, a change in intracellular calcium levels, a change in the agonist-induced induction of phospholipase C activity and/or a change in cAMP production. As far as the change in intracellular calcium levels is regarded, the use of binding partners which bring about an increase in intracellular calcium levels is a particular embodiment of the invention.
Examples of suitable pharmaceutical formulations are solid pharmaceutical forms, such as powders, granules, tablets, pastilles, sachets, cachets, coated tablets, capsules such as hard and soft gelatin capsules, suppositories or vaginal pharmaceutical forms, semisolid pharmaceutical forms, such as ointments, creams, hydrogels, pastes or patches, and also liquid pharmaceutical forms, such as solutions, emulsions, in particular oil-in-water emulsions, suspensions, for example lotions, injection and infusion preparations, eye and ear drops. Implanted delivery devices can also be used for the administration of binding partners according to the invention. In addition, liposomes, microspheres or polymer matrices can also be used.
In the production of the compositions, binding partners according to the invention are usually mixed or diluted with an excipient.
Excipients can be solid, semisolid or liquid materials which are used as a vehicle or medium for the active compound.
Suitable excipients include, for example, lactose, dextrose, sucrose, sorbitol, mannitol, starches, acacia gum, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup and methylcellulose. In addition, the formulations can comprise pharmaceutically acceptable vehicles or customary excipients, such as lubricants, for example tallow, magnesium stearate and mineral oil; wetting agents; emulsifying and suspending agents; preservatives, such as methyl and propyl hydroxybenzoates; antioxidants; antiirritants; chelating agents;
coating auxiliaries; emulsion stabilizers; film-forming agents;
gel-forming agents; flavor-masking agents; flavor corrigents;
resins; hydrocolloids; solvents; solubilizers; neutralizing agents; permeation accelerators; pigments; quaternary ammonium compounds; refatting and superfatting agents; ointment, cream or oil bases; silicone derivatives; spreading auxiliaries;
stabilizers; sterilizing agents; suppository bases; tablet excipients, such as binders, fillers, lubricants, disintegrants or coatings; propellants; drying agents; opacifying agents;
thickeners; waxes; plasticizers; white oils. A relevant embodiment is based on expert knowledge, such as is presented, for example, in Fiedler, H.P., Lexikon der Hilfsstoffe fir Pharmazie, Kosmetik and angrenzende Gebiete [Encyclopedia of excipierits for pharmacy, cosmetics and related areas], 4th Edition, Aulendorf: ECV-Editio-Kantor-Verlag, 1996.
The present invention also relates to the use of a binding partner for 5-HT5 receptors and in particular of the abovementioned particular and preferred embodiments of binding partners according to the invention for the treatment of migrainous cerebrovascular disorders, especially for the treatment of migraine and other vascular-related headaches, in particular paroxysmal headaches of the migraine type. These include the disorders described as simple and as classical migraine without or with concomitant neurological functional disorders, true and atypical migraine, and also more specific disorders of this type, for example, associated migraine, so-called migraine equivalents, digestive migraine, ophthalmic migraine, ophthalmoplegic migraine, migraine rouge, also described as cluster headache (Horton's syndrome) and cervical migraine. Treatment is understood as meaning both prophylactic therapy, in particular prophylaxis against recurring attacks, for example as interval treatment, and treatment in the case of acute symptoms, in particular during the headache phases. Successful treatment leads to a reduction of the intensity of the symptoms, in particular of the headache, of neurological functional disorders, e.g. of visual, sensory, motor disorders and speech disorders, nausea and retching, and/or of the attack frequency.
Acute treatment of migraine with binding partners is preferred.
The invention in particular also relates to the use of the binding partners mentioned for the treatment of those forms of disorders mentioned above in whose formation and/or course 5-HT5 receptors are involved, i.e. disorders which are modulated by a 5-HT5 receptor activity.
The term "disorder" in the sense according to the invention describes anomalies which as a rule are regarded as pathological conditions and can reveal themselves in the form of certain signs, symptoms and/or malfunctions. The treatment according to the invention can be directed at individual disorders, say anomalies or pathological conditions, but also a number of anomalies which are causally connected with one another can be summarized to give patterns, i.e. syndromes, which can be treated according to the invention.
A treatment within the meaning according to the invention comprises not only the treatment of acute or chronic signs, symptoms and/or malfunctions but also a preventive treatment (prophylaxis), in particular as relapse or phase prophylaxis. The treatment can be accomplished symptomatically, for example as symptom-suppression. It can be carried out short-term, be accomplished medium-term, or it can also be a long-term 5 treatment, for example in the context of maintenance therapy.
Binding partners which can be used for migraine treatment can bind to 5-HT5 with a lower, an essentially identical, or a higher affinity than to a specific receptor which is different from 10 5-HT5.
Binding partners for 5-HT5 receptors with respect to the use according to the invention thus in particular include those whose binding affinity for 5-HT5 receptors compared with the affinity 15 for 5-HT1 receptors, in particular 5-HT1B and/or 5-HT1D, is so high that they are advantageously suitable for the use according to the invention. This does not necessarily presuppose a comparatively more selective binding to 5-HT5 receptors, even those selective binding partners for 5-HT5 receptors are a particular embodiment of the present invention.
For example, binding partners can be used which have a high affinity both for 5-HT5 and for 5-HT1 receptors, in particular for 5-HT1B and/or 5-HT1D. High affinity in this connection means Ki values as a rule in the range from 1-10-9 M to 1.10-6 M.
According to a particular embodiment, in the high-affinity range usable binding partners have, relative to 5-HT receptors, a binding profile that is marked by a binding affinity to 5-HT5 which, in comparison with other binding affinities of this range is essentially identical or only slightly less. Factors of 10 or less can be advantageous.
According to a further embodiment of the invention, the selective 5-HT5 binding partners described previously are employed.
According to a particular embodiment of the present invention, binding partners are employed whose binding, at least to 5-HT5 receptors of h5-HT5-transfected CHO cells, brings about a change in the agonist-induced stimulation of the GTP binding to membrane-bound G proteins, a change in intracellular calcium levels, a change in the agonist-induced induction of phospholipase C activity and/or a change in cAMP production. As far as the change in intracellular calcium levels is regarded, the use of binding partners which bring about an increase in intracellular calcium levels is a particular embodiment of the invention.
The present invention is illustrated in greater detail by means of the following examples, without being restricted thereto.
Example 1 h5-HT5 receptor-expressing HEK293 cells and CHO cells The gene coding for the human 5-HT5 receptor was isolated from human tissues in a known manner by means of 3'-5'-RT-PCR (RACE
system, Boehringer Mannheim). The gene sequence was then inserted into a plasmid carrying the neomycin resistance gene (pcDNA3;
Invitrogen, Germany) and amplified in E. coli according to the manufacturer's instructions. A preparation of the resulting plasmid was mixed with Lipofectamin (Gibco Life-Sciences, Germany), and HEK293 cells were incubated with a thin layer of this transfection mixture in petri dishes (2.5 cm). The transfection mixture was then replaced by neomycin-containing culture medium. Surviving cells were further cultured in DM'4EM-F12 medium which was supplemented with 10% fetal calf serum, 2 mM
glutamine and antibiotics (90 mg of streptomycin, 90 mg of penicillin). The cells were grown to confluence under 5% CO, 295%
atmospheric humidity and 37 C.
h5-HT5 receptor-expressing CHO cells are obtained analogously.
Example 2 Cell membrane preparation The method used here essentially follows known methods for the preparation of cell membranes from cells (Findlay J.B.C. and Evans W.H., Biological Membranes, Practical Approach (1987)). The cells cultured according to Reference Example 1 were carefully scraped off the surface of the culture vessel and centrifuged in DMEM-F12 medium at 180xg for 10 min. The cell pellets obtained were resuspended in 5 mM tris HC1 buffer containing 5 mM EDTA, 5 mM EGTA, 0.1 mM PMSF and 3 mM benzamidine (pH: 7.6; buffer A) and incubated at 4 C for 15 min. The cell suspension was homogenized (6 X 3s) in an UltraturraxR (15,000 rpm) and centrifuged at 1000 X g and 4 C for 1 min. The pellet was resuspended in buffer A and, as described above, homogenized and centrifuged. The supernatants from both steps were collected and centrifuged at 40,000x g and 4 C for 20 min. The pellet was resuspended and homogenized in buffer A (1X15s). The membrane suspension was centrifuged at 40,000 X g and 4 C for 20 min. The resulting pellet was resuspended in buffer A containing 10%
Example 1 h5-HT5 receptor-expressing HEK293 cells and CHO cells The gene coding for the human 5-HT5 receptor was isolated from human tissues in a known manner by means of 3'-5'-RT-PCR (RACE
system, Boehringer Mannheim). The gene sequence was then inserted into a plasmid carrying the neomycin resistance gene (pcDNA3;
Invitrogen, Germany) and amplified in E. coli according to the manufacturer's instructions. A preparation of the resulting plasmid was mixed with Lipofectamin (Gibco Life-Sciences, Germany), and HEK293 cells were incubated with a thin layer of this transfection mixture in petri dishes (2.5 cm). The transfection mixture was then replaced by neomycin-containing culture medium. Surviving cells were further cultured in DM'4EM-F12 medium which was supplemented with 10% fetal calf serum, 2 mM
glutamine and antibiotics (90 mg of streptomycin, 90 mg of penicillin). The cells were grown to confluence under 5% CO, 295%
atmospheric humidity and 37 C.
h5-HT5 receptor-expressing CHO cells are obtained analogously.
Example 2 Cell membrane preparation The method used here essentially follows known methods for the preparation of cell membranes from cells (Findlay J.B.C. and Evans W.H., Biological Membranes, Practical Approach (1987)). The cells cultured according to Reference Example 1 were carefully scraped off the surface of the culture vessel and centrifuged in DMEM-F12 medium at 180xg for 10 min. The cell pellets obtained were resuspended in 5 mM tris HC1 buffer containing 5 mM EDTA, 5 mM EGTA, 0.1 mM PMSF and 3 mM benzamidine (pH: 7.6; buffer A) and incubated at 4 C for 15 min. The cell suspension was homogenized (6 X 3s) in an UltraturraxR (15,000 rpm) and centrifuged at 1000 X g and 4 C for 1 min. The pellet was resuspended in buffer A and, as described above, homogenized and centrifuged. The supernatants from both steps were collected and centrifuged at 40,000x g and 4 C for 20 min. The pellet was resuspended and homogenized in buffer A (1X15s). The membrane suspension was centrifuged at 40,000 X g and 4 C for 20 min. The resulting pellet was resuspended in buffer A containing 10%
glycerol and 1% bovine serum albumin. Aliquots were frozen and stored at -800C until use.
'Example 3 Kinetics of the saturation binding of [3H]-5-CT
The methodology is essentially known (Ress S. et al., FEBS
Letters 335:242-246 (1994)). Membranes obtained according to Reference Example 2 (200 l) were incubated in a total volume of 600 l in 100 mM tris HC1 containing 1 mM EDTA (pH: 7.7; buffer B) with increasing concentrations of [3H]-5-CT (96 Ci/mmol), 10 M methiothepine being added for the determination of the specific binding, while methiothepine was not added for the determination of the total binding. The mixture was incubated at 30 C for 90 min. The samples were then filtered, a SkatronR
filtration system and GF/B filters embedded in 0.3%
polyethyleneimide being used. The filters were washed at 4 C with 9 ml of buffer B. The radioactivity retained on the filters was measured by means of liquid scintillation counting, 5 ml of Ultima-Gold (Packard) being used.
Example 4 '[3H]-5-CT binding competition The experiments on binding competition were carried out essentially following known investigations (Rees et al., 1994).
Membranes obtained according to Example 2 (200 l) were incubated in the presence of 2 nM [3H]-5-CT in a total volume of 600 l in buffer B with increasing concentrations of selected compounds.
After an incubation time of 75 min at 30 C, the samples were filtered-at 40C through GF/B filters embedded in 0.3%
polyethyleneimide using buffer B. The filters were washed with 9 .ml of buffer B. The radioactivity retained on the filters was determined as in Reference Example 3. The total binding was defined as that binding of the radioligand which was observed without addition of further compounds.. This nonspecific binding was defined as that binding of [3H]-5-CT which was observed in the presence of 10 pM methiothepine. Similar systems can also be used which, as a result of use of microtiter plates, allow a high sample throughput and secondary screening.
The saturation parameters of the [3H]-5-CT binding was determined both by nonlinear regression analysis and from linear plots using the SigmaPlot software (Jandel Scientific, Germany). Competition curves were set up in which the radioactive binding is expressed as a percentage proportion of the total binding. Half-maximal inhibition constants IC50 and Hill coefficients (nH) were determined by means of nonlinear regression analysis.
b) Identification of h5-HT5 receptor ligands by HTS using FlashPlate technology.
96-well FlashPlates which are coated with h5-HT5 membranes can be obtained from Bio Signal Inc. (Canada). [3H]-LSD was diluted to a suitable concentration in Tris HC1 buffer which contains 10 mm MgC12, 0.5 mM EDTA and 0.5% of BSA. The radio ligand solution was added to the wells (25 ml), which either contained test compound or did not contain test compound. The plates were incubated at room temperature for 180 minutes and the radioactive signal was measured using a micro A-counter (Wallac). The nonspecific binding was determined using methiothepine. [3H]-LSD has an affinity of 12 nM. With increasing binding affinity of the test compound, the radioactive signal of [3H]-LSD decreased.
Example 5 Determination of the agonist-induced stimulation of [35S]GT:PyS
binding [35S]GTPyS binding assays are known. The present assay was carried out following the previously described method of Hilf, G. and Jakobs, K.H. (Eur. J. Mol. Pharmacol. 225:245-252 (1992)). Active compound-induced changes in the [35S]GTPyS binding to membranes of HEK293 cells stably transfected with the h5-HT5 receptor gene were measured (see Reference Examples 1 and 2). The cell membranes (12 g) were incubated with 50 mM triethanolamine HCl buffer (pH: 7.5) containing 6.75mM MgC12, 150 mM NaCl, 1 mM DTT, 1 mM EDTA, 10 M GDP and (35S]GTPyS. Following a 60-minute incubation at 30 C with or without addition of the active compounds to be tested, the test mixture (100 l) was rapidly filtered through GF-B filters using a SkatronR filtration device.
The filters were rapidly washed with 50 mM tris HC1 buffer (9 ml;
pH: 7.5; 4 C) containing 100 mM NaCl and 5 mM MgC12. The radioactivity retained on the filters was determined by means of scintillation spectrometry, Ultima Gold scintillation fluid being used. Similar systems which allow a high throughput and secondary screening as a result of use of microtiter plates can likewise be used.
The active compound activities were expressed as a percentage proportion of the basic binding measured in the absence of the active compound. The matching of the curves was carried out using software for nonlinear regression analysis (SigmaPlot, Jandel Scientific, Germany) according to the general equation E=(L X Emax)/(L+EC50), in which E is the efficacy, L is the ligand concentration, Emax is the maximum efficacy and EC50 is that concentration which induces 50% of the maximal efficacy.
Example 6 Determination of the agonist-induced change in intracellular calcium levels The method is known (Kao J.P.Y., Methods in Cell Biology 40:155-181 (1994)). As described in Reference Example 1, h5-HT5 receptor-expressing HEK293 cells were grown in culture vessels.
The cells were carefully scraped off before they were confluent.
The cells were labeled with Fura 2 by incubating at room temperature with Fura 2-acetylmethyl ester (Sigma). The cells were centrifuged at 180x g for 10 min and resuspended in DMEM-F12 medium without serum and incubated at 37 C, 5% C02 and 95%
atmospheric humidity for 45 min.
Intracellular calcium levels were determined with a fluorescence microscope which was equipped with a suitable filter exchange system (Olympus/Hamamatsu). The fluorescence ratio (340 nm/380 nm) was determined using the ArgusR software. The intracellular calcium levels were observed for a short time in individual cells without the addition of active compounds and then 30 min after addition of the active compound to be tested.
Similar systems which permitted a high throughput and secondary screening as a result of the use of microtiter plates could likewise be used.
Analogously, the modulation of intracellular Ca2+ levels can be assessed in the HTS. For this, h5-HT5 receptor-expression CHO
cells were cultured overnight in 96-well plates (30,0000 [sic] -80,000 cells/well). The cells were labeled for one hour using HEPES buffer containing 1 mM Fluo-3-AM, 10% of pluronic acid and 2.5 mM probencid. A test compound was added to each well. For the determination of the calcium levels, the fluorescence intensity was read off using a fluorimetrically operating plate reader (Fluorometric Imaging Plate Reader; FLIPR).
Example 7 Determination of the agonist-induced phospholipase C activity 5 The method is essentially known (Garcia-Ladona F.J. et al., Neuroreport 4:691-694 (1993)). The cells were incubated with 0.125 pM [3H]myoinositol for 24 h. Unincorporated [3H]myoinositol was removed from the medium and replaced by Krebs-Henseleit buffer containing 10 mM LiCl. After incubation for 10 minutes, 10 the active compound to be tested was added: After 45 min, the reaction was stopped by replacing the stimulation medium by distilled water. If tissue samples are used, a similar procedure is employed (Garcia-Ladona et al., 1993). The cells were frozen and stored at -80 C. The production of [3H]inositol monophosphate 15 was determined by means of known chromatographic methods. A
similar method can be used with tissue miniprisms. The determination of the phospholipase C stimulation was likewise carried out in a similar manner by preparing membrane fractions, as described in Reference Example 2, and incubating with [32P]PIP2 20 and active compounds. In this case, the production of IP3 was determined. Known processes were also optimized in order to use systems based on microtiter plates. Commercially obtainable materials allow extension to analyses with a high throughput and the carrying-out of secondary screening.
Example 8 Determination of the agonist-induced change in cAMP production The method used is essentially known (Strada S.S. et al., Methods in Neurotransmission receptor analysis: 89-110 (1990)). Cells were incubated in culture medium without serum and antibiotics for 10 min. The medium was heated at 95 C for 15 min in order to stop the reaction. The cell samples were frozen and stored at -800C. cAMP.levels were determined using commercially obtainable kits which use the cAMP binding protein. Known processes were also optimized in order to use systems based on microtiter plates. Commercially obtainable materials allow extension to analyses with a high throughput and the carrying-out of secondary screening.
'Example 3 Kinetics of the saturation binding of [3H]-5-CT
The methodology is essentially known (Ress S. et al., FEBS
Letters 335:242-246 (1994)). Membranes obtained according to Reference Example 2 (200 l) were incubated in a total volume of 600 l in 100 mM tris HC1 containing 1 mM EDTA (pH: 7.7; buffer B) with increasing concentrations of [3H]-5-CT (96 Ci/mmol), 10 M methiothepine being added for the determination of the specific binding, while methiothepine was not added for the determination of the total binding. The mixture was incubated at 30 C for 90 min. The samples were then filtered, a SkatronR
filtration system and GF/B filters embedded in 0.3%
polyethyleneimide being used. The filters were washed at 4 C with 9 ml of buffer B. The radioactivity retained on the filters was measured by means of liquid scintillation counting, 5 ml of Ultima-Gold (Packard) being used.
Example 4 '[3H]-5-CT binding competition The experiments on binding competition were carried out essentially following known investigations (Rees et al., 1994).
Membranes obtained according to Example 2 (200 l) were incubated in the presence of 2 nM [3H]-5-CT in a total volume of 600 l in buffer B with increasing concentrations of selected compounds.
After an incubation time of 75 min at 30 C, the samples were filtered-at 40C through GF/B filters embedded in 0.3%
polyethyleneimide using buffer B. The filters were washed with 9 .ml of buffer B. The radioactivity retained on the filters was determined as in Reference Example 3. The total binding was defined as that binding of the radioligand which was observed without addition of further compounds.. This nonspecific binding was defined as that binding of [3H]-5-CT which was observed in the presence of 10 pM methiothepine. Similar systems can also be used which, as a result of use of microtiter plates, allow a high sample throughput and secondary screening.
The saturation parameters of the [3H]-5-CT binding was determined both by nonlinear regression analysis and from linear plots using the SigmaPlot software (Jandel Scientific, Germany). Competition curves were set up in which the radioactive binding is expressed as a percentage proportion of the total binding. Half-maximal inhibition constants IC50 and Hill coefficients (nH) were determined by means of nonlinear regression analysis.
b) Identification of h5-HT5 receptor ligands by HTS using FlashPlate technology.
96-well FlashPlates which are coated with h5-HT5 membranes can be obtained from Bio Signal Inc. (Canada). [3H]-LSD was diluted to a suitable concentration in Tris HC1 buffer which contains 10 mm MgC12, 0.5 mM EDTA and 0.5% of BSA. The radio ligand solution was added to the wells (25 ml), which either contained test compound or did not contain test compound. The plates were incubated at room temperature for 180 minutes and the radioactive signal was measured using a micro A-counter (Wallac). The nonspecific binding was determined using methiothepine. [3H]-LSD has an affinity of 12 nM. With increasing binding affinity of the test compound, the radioactive signal of [3H]-LSD decreased.
Example 5 Determination of the agonist-induced stimulation of [35S]GT:PyS
binding [35S]GTPyS binding assays are known. The present assay was carried out following the previously described method of Hilf, G. and Jakobs, K.H. (Eur. J. Mol. Pharmacol. 225:245-252 (1992)). Active compound-induced changes in the [35S]GTPyS binding to membranes of HEK293 cells stably transfected with the h5-HT5 receptor gene were measured (see Reference Examples 1 and 2). The cell membranes (12 g) were incubated with 50 mM triethanolamine HCl buffer (pH: 7.5) containing 6.75mM MgC12, 150 mM NaCl, 1 mM DTT, 1 mM EDTA, 10 M GDP and (35S]GTPyS. Following a 60-minute incubation at 30 C with or without addition of the active compounds to be tested, the test mixture (100 l) was rapidly filtered through GF-B filters using a SkatronR filtration device.
The filters were rapidly washed with 50 mM tris HC1 buffer (9 ml;
pH: 7.5; 4 C) containing 100 mM NaCl and 5 mM MgC12. The radioactivity retained on the filters was determined by means of scintillation spectrometry, Ultima Gold scintillation fluid being used. Similar systems which allow a high throughput and secondary screening as a result of use of microtiter plates can likewise be used.
The active compound activities were expressed as a percentage proportion of the basic binding measured in the absence of the active compound. The matching of the curves was carried out using software for nonlinear regression analysis (SigmaPlot, Jandel Scientific, Germany) according to the general equation E=(L X Emax)/(L+EC50), in which E is the efficacy, L is the ligand concentration, Emax is the maximum efficacy and EC50 is that concentration which induces 50% of the maximal efficacy.
Example 6 Determination of the agonist-induced change in intracellular calcium levels The method is known (Kao J.P.Y., Methods in Cell Biology 40:155-181 (1994)). As described in Reference Example 1, h5-HT5 receptor-expressing HEK293 cells were grown in culture vessels.
The cells were carefully scraped off before they were confluent.
The cells were labeled with Fura 2 by incubating at room temperature with Fura 2-acetylmethyl ester (Sigma). The cells were centrifuged at 180x g for 10 min and resuspended in DMEM-F12 medium without serum and incubated at 37 C, 5% C02 and 95%
atmospheric humidity for 45 min.
Intracellular calcium levels were determined with a fluorescence microscope which was equipped with a suitable filter exchange system (Olympus/Hamamatsu). The fluorescence ratio (340 nm/380 nm) was determined using the ArgusR software. The intracellular calcium levels were observed for a short time in individual cells without the addition of active compounds and then 30 min after addition of the active compound to be tested.
Similar systems which permitted a high throughput and secondary screening as a result of the use of microtiter plates could likewise be used.
Analogously, the modulation of intracellular Ca2+ levels can be assessed in the HTS. For this, h5-HT5 receptor-expression CHO
cells were cultured overnight in 96-well plates (30,0000 [sic] -80,000 cells/well). The cells were labeled for one hour using HEPES buffer containing 1 mM Fluo-3-AM, 10% of pluronic acid and 2.5 mM probencid. A test compound was added to each well. For the determination of the calcium levels, the fluorescence intensity was read off using a fluorimetrically operating plate reader (Fluorometric Imaging Plate Reader; FLIPR).
Example 7 Determination of the agonist-induced phospholipase C activity 5 The method is essentially known (Garcia-Ladona F.J. et al., Neuroreport 4:691-694 (1993)). The cells were incubated with 0.125 pM [3H]myoinositol for 24 h. Unincorporated [3H]myoinositol was removed from the medium and replaced by Krebs-Henseleit buffer containing 10 mM LiCl. After incubation for 10 minutes, 10 the active compound to be tested was added: After 45 min, the reaction was stopped by replacing the stimulation medium by distilled water. If tissue samples are used, a similar procedure is employed (Garcia-Ladona et al., 1993). The cells were frozen and stored at -80 C. The production of [3H]inositol monophosphate 15 was determined by means of known chromatographic methods. A
similar method can be used with tissue miniprisms. The determination of the phospholipase C stimulation was likewise carried out in a similar manner by preparing membrane fractions, as described in Reference Example 2, and incubating with [32P]PIP2 20 and active compounds. In this case, the production of IP3 was determined. Known processes were also optimized in order to use systems based on microtiter plates. Commercially obtainable materials allow extension to analyses with a high throughput and the carrying-out of secondary screening.
Example 8 Determination of the agonist-induced change in cAMP production The method used is essentially known (Strada S.S. et al., Methods in Neurotransmission receptor analysis: 89-110 (1990)). Cells were incubated in culture medium without serum and antibiotics for 10 min. The medium was heated at 95 C for 15 min in order to stop the reaction. The cell samples were frozen and stored at -800C. cAMP.levels were determined using commercially obtainable kits which use the cAMP binding protein. Known processes were also optimized in order to use systems based on microtiter plates. Commercially obtainable materials allow extension to analyses with a high throughput and the carrying-out of secondary screening.
Example 9 Tissue preparation 90 min after administration of the active compound (orally, intraperitoneally, intravenously or intracerebroventricularly), the experimental animals were decapitated. The entire brain was rapidly removed from the skull, frozen on dry ice and stored at -80 C. Rat brain sections (15 m) were obtained in a cryostat at -20 C, applied to gelatin-coated slides and stored at -30 C until use.
Example A
According to Example 3, the binding affinity. of [3H]-5-CT to 5-HT5 receptors was determined. Figure 1 shows a plot of bound (3H]-5-CT as a function of the [3H]-5-CT concentration. A
dissociation constant of Kd = 0.570 nM was determined. Depending on the clonal cell line, the receptor binding density (B) varied in a range from 900-28,000 fmol/mg of protein.
Example B
According to Example 4, the binding affinities of serotoninergic compounds were determined by means of [3H]-5-CT
binding competition. The following IC50 values were obtained:
Compound IC50 [M]
R(+)-8-OH-DPAT 6.75.10-7 Methiothepine 6.2.10-10 Dihydroergotamine 1.79.10-8 Sumatriptan 7.6.10-6 Methysergide 1.48.10-7 R(+)-Lisuride 8.2.10-9 Buspirone inactive In a further test series, the inhibition constants K1 of the following compounds were also determined (Ki = IC50/(1+C/Kd)), where C is the concentration of (3H]-5-CT and Kd was determined according to Example A):
Example A
According to Example 3, the binding affinity. of [3H]-5-CT to 5-HT5 receptors was determined. Figure 1 shows a plot of bound (3H]-5-CT as a function of the [3H]-5-CT concentration. A
dissociation constant of Kd = 0.570 nM was determined. Depending on the clonal cell line, the receptor binding density (B) varied in a range from 900-28,000 fmol/mg of protein.
Example B
According to Example 4, the binding affinities of serotoninergic compounds were determined by means of [3H]-5-CT
binding competition. The following IC50 values were obtained:
Compound IC50 [M]
R(+)-8-OH-DPAT 6.75.10-7 Methiothepine 6.2.10-10 Dihydroergotamine 1.79.10-8 Sumatriptan 7.6.10-6 Methysergide 1.48.10-7 R(+)-Lisuride 8.2.10-9 Buspirone inactive In a further test series, the inhibition constants K1 of the following compounds were also determined (Ki = IC50/(1+C/Kd)), where C is the concentration of (3H]-5-CT and Kd was determined according to Example A):
Compound Ki [M]
R(+)-8-OH-DPAT 1.25.10-7 5-CT 1.44.10-9 Dihydroergotamine 4.05.10-9 Sumatriptan 8.12.10-7 Methysergide 1.54.10-8 Example C
According to Example 5, the active compound-induced binding of GTP to G proteins was investigated. The coupling of 5-HT5 receptors to G proteins in HEK293 cells was evident. The typical serotoninergic agonists 5-HT and 5-CT induced an increase in the (35S]GTPyS.binding to the cell membranes of over 40% above the base value (see Figure 2). The 5-HT5 receptor needs GDP for the coupling to G proteins, which is mediated by agonists (see Figure 3A). The 5-HT effect was dose-dependent (see Figure 4) with an EC50 of 2.6 M.
Example D
The active compound-induced effect on intracellular calcium levels was investigated according to Example 6. The stimulation of the 5-HT5 receptors with R(+)-lisuride (1 ECM) in HEK293 cells induced a rise in intracellular Ca2+ (see Figure 5).
R(+)-8-OH-DPAT 1.25.10-7 5-CT 1.44.10-9 Dihydroergotamine 4.05.10-9 Sumatriptan 8.12.10-7 Methysergide 1.54.10-8 Example C
According to Example 5, the active compound-induced binding of GTP to G proteins was investigated. The coupling of 5-HT5 receptors to G proteins in HEK293 cells was evident. The typical serotoninergic agonists 5-HT and 5-CT induced an increase in the (35S]GTPyS.binding to the cell membranes of over 40% above the base value (see Figure 2). The 5-HT5 receptor needs GDP for the coupling to G proteins, which is mediated by agonists (see Figure 3A). The 5-HT effect was dose-dependent (see Figure 4) with an EC50 of 2.6 M.
Example D
The active compound-induced effect on intracellular calcium levels was investigated according to Example 6. The stimulation of the 5-HT5 receptors with R(+)-lisuride (1 ECM) in HEK293 cells induced a rise in intracellular Ca2+ (see Figure 5).
Claims (7)
1. An in vitro screening process for the identification of compounds for the treatment of migrainous cerebrovascular disorders, which comprises determining the affinity of the compounds for a 5-HT5 receptor, and selecting HT5 binding partners whose binding affinity for the 5-HT5 receptor is at least times greater than their binding affinity for the 5-HT1D receptor.
2. The process as claimed in claim 1, wherein the binding affinity of the 5-HT5 binding partners for the 5-HT5 receptor is at least 20-times greater than their binding affinity for the 5-HT1D receptor.
3. The process as claimed in claim 1, wherein the binding affinity of the 5-HT5 binding partners for the 5-HT5 receptor is at least 50-times greater than their binding affinity for the 5-HT1D receptor.
4. The process as claimed in any one of claims 1 to 3, wherein the K i value of the 5-HT5 binding partners for binding to the 5-HT5 receptor is less than M.
5. The process as claimed in any one of claims 1 to 4, wherein, for determining binding affinity, the compounds are brought into contact with cellular systems having the 5-HT5 receptor.
6. The process as claimed in claim 5, wherein human glioma cell lines or h5-HT5-transfected heterologous cell lines are used.
7. The process as claimed in claim 6, where h5-HT5-transfected CHO cells, h5-HT5-transfected human kidney cells, or h5-HT5-transfected C-6 glioma cells are used.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19900674A DE19900674A1 (en) | 1999-01-11 | 1999-01-11 | Binding partner for 5-HT5 receptors for migraine treatment |
DE19900674.1 | 1999-01-11 | ||
PCT/EP2000/000142 WO2000041472A2 (en) | 1999-01-11 | 2000-01-11 | Binding partners for 5-ht5-receptors for the treatment of migraine |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2359360A1 CA2359360A1 (en) | 2000-07-20 |
CA2359360C true CA2359360C (en) | 2012-11-27 |
Family
ID=7893919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2359360A Expired - Fee Related CA2359360C (en) | 1999-01-11 | 2000-01-11 | In vitro screening method for identifying selective binding partners for 5-ht5-receptors |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1144050A2 (en) |
JP (1) | JP2002540063A (en) |
CN (1) | CN1321635C (en) |
AU (1) | AU2289100A (en) |
CA (1) | CA2359360C (en) |
DE (1) | DE19900674A1 (en) |
MX (1) | MXPA01006986A (en) |
WO (1) | WO2000041472A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004008141A1 (en) | 2004-02-19 | 2005-09-01 | Abbott Gmbh & Co. Kg | Guanidine compounds and their use as binding partners for 5-HT5 receptors |
WO2007022947A2 (en) | 2005-08-21 | 2007-03-01 | Abbott Gmbh & Co. Kg | 5-ring heteroaromatic compounds and their use as binding partners for 5-ht5 receptors |
US9296697B2 (en) | 2005-08-24 | 2016-03-29 | Abbott Laboratories | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8770282A (en) * | 1981-08-27 | 1983-03-03 | Shaun R. Coughlin | Composition for the treatment of atherosclerosis |
US5360735A (en) * | 1992-01-08 | 1994-11-01 | Synaptic Pharmaceutical Corporation | DNA encoding a human 5-HT1F receptor, vectors, and host cells |
FR2693200B1 (en) * | 1992-07-01 | 1994-08-19 | Inst Nat Sante Rech Med | New polypeptides having serotonergic receptor activity, nucleic acids encoding these polypeptides and uses. |
FR2701265B1 (en) * | 1993-02-09 | 1995-04-07 | Inst Nat Sante Rech Med | New polypeptides having serotoninergic receptor activity, nucleic acids encoding these polypeptides and uses. |
-
1999
- 1999-01-11 DE DE19900674A patent/DE19900674A1/en not_active Withdrawn
-
2000
- 2000-01-11 AU AU22891/00A patent/AU2289100A/en not_active Abandoned
- 2000-01-11 CA CA2359360A patent/CA2359360C/en not_active Expired - Fee Related
- 2000-01-11 EP EP00901526A patent/EP1144050A2/en not_active Ceased
- 2000-01-11 JP JP2000593096A patent/JP2002540063A/en active Pending
- 2000-01-11 MX MXPA01006986A patent/MXPA01006986A/en not_active IP Right Cessation
- 2000-01-11 WO PCT/EP2000/000142 patent/WO2000041472A2/en active Application Filing
- 2000-01-11 CN CNB008046107A patent/CN1321635C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1144050A2 (en) | 2001-10-17 |
MXPA01006986A (en) | 2002-09-18 |
JP2002540063A (en) | 2002-11-26 |
DE19900674A1 (en) | 2000-07-13 |
WO2000041472A3 (en) | 2001-10-11 |
WO2000041472A2 (en) | 2000-07-20 |
CN1321635C (en) | 2007-06-20 |
AU2289100A (en) | 2000-08-01 |
CA2359360A1 (en) | 2000-07-20 |
CN1342070A (en) | 2002-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120196301A1 (en) | Use of binding partners for 5-ht5 receptors for the treatment of neurodegenerative and neuropsychiatric disorders | |
Friedlander et al. | Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves αv and β1 integrins | |
Schulz et al. | Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A | |
Zheng et al. | Glut1/SLC2A1 is crucial for the development of the blood‐brain barrier in vivo | |
Kulaksiz et al. | Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies | |
Peress et al. | Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain | |
Bussiere et al. | Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine | |
US20100028333A1 (en) | Receptor for amyloid beta and uses thereof | |
JP5847755B2 (en) | Methods for detecting cells and agents useful for the same | |
Nagy et al. | Neuronal cyclin expression in the hippocampus in temporal lobe epilepsy | |
Eikermann-Haerter et al. | Animal models of migraine headache and aura | |
Lentz et al. | Myoplasmic calcium regulation in myotubes from horses with recurrent exertional rhabdomyolysis | |
CA2359360C (en) | In vitro screening method for identifying selective binding partners for 5-ht5-receptors | |
JP2009503520A (en) | Beta-amyloid receptor and use thereof | |
KR20010031830A (en) | Antibodies against phosphorylated VASP(vasodilator-stimulated phosphoprotein), hybridoma cells for their preparation, and their use | |
WO2007123274A1 (en) | Novel marker for sensitivity against sulfonamide compound | |
US20170056500A1 (en) | FKBP52-Tau Interaction as a Novel Therapeutical Target for Treating the Neurological Disorders Involving Tau Dysfunction | |
Styren et al. | Epidermal growth factor receptor expression in demented elderly: localization to vascular endothelial cells of brain, pituitary and skin | |
KR100756423B1 (en) | Method for searching myelin using gonadotropin releasing hormone receptors as a new biomaker | |
AU2002246766B2 (en) | Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof | |
Kloss | Investigating the effects of extracellular biomolecules on Aß1-42 oligomer uptake and trafficking by microglia cells | |
Becker et al. | 2. TUMORS OF THE CENTRAL | |
AU2002246766A1 (en) | Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof | |
Garcia et al. | Caveolin-1 Influences LFA-1 Redistribution | |
Ricciarelli et al. | American Association of Neuropathologists, Inc. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20150112 |